Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06690281CT.gov A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Intestine Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Kras Tcr-Transduced Pbl (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Etoposide | Cancer Research UK | P2 | BB |
| Vincristine Sulfate | Cancer Research UK | P2 | BB |
| Nivestim | Cancer Research UK | P2 | BB |
| Carboplatin | National Cancer Institute (NCI) | P2 | B |
| Prednisone | City of Hope Medical Center | P2 | B |
| Adriamycin | Cancer Research UK | P2 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P2 | B |
+41 more in the Small Intestine Cancer cohort
Other indications for Kras Tcr-Transduced Pbl
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm | — | P2 | B · 59 |
| Hepatocellular Carcinoma | — | P2 | CCC · 53 |
| Digestive System Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Kras Tcr-Transduced Pbl in Small Intestine Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/kras-tcr-transduced-pbl-small-intestine-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →